Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis

Antimicrob Agents Chemother. 2006 May;50(5):1852-4. doi: 10.1128/AAC.50.5.1852-1854.2006.

Abstract

Nebulized amphotericin B (AMB) combined with intravenous AMB was studied in persistently leukopenic rats with invasive pulmonary aspergillosis. Pulmonary concentrations of AMB after aerosol treatment were substantially higher than after intravenous liposomal AMB. Nebulized liposomal AMB in addition to intravenous AMB resulted in significantly prolonged survival compared to controls.

MeSH terms

  • Amphotericin B / administration & dosage*
  • Amphotericin B / pharmacology
  • Animals
  • Antifungal Agents / administration & dosage*
  • Antifungal Agents / pharmacology
  • Aspergillosis / drug therapy*
  • Aspergillus fumigatus / drug effects*
  • Biomarkers / metabolism
  • Injections, Intravenous
  • Liposomes
  • Lung Diseases, Fungal / drug therapy*
  • Lung Diseases, Fungal / microbiology
  • Nebulizers and Vaporizers / microbiology
  • Rats
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antifungal Agents
  • Biomarkers
  • Liposomes
  • Amphotericin B